Eti Mitrany
Director/Board Member at BRAINSWAY LTD.
Net worth: - $ as of 2024-03-30
Profile
Eti Mitrany is currently an Independent Director at Brainsway Ltd.
and a Director at Trioxnano Ltd.
Previously, she worked at Teva Pharmaceutical Industries Ltd.
for 25 years, where she held the position of Senior Vice President-Head of Economic from 2012 to 2020.
She also served as the Global Chief Financial Officer at Copaxone.
In 2021-2022, she was the Chief Financial Officer & Head-Corporate Strategy at CytoReason Ltd.
Ms. Mitrany received her undergraduate degree in 1994 and her MBA in 1997, both from Tel-Aviv University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BRAINSWAY LTD
-.--% | 2024-03-17 | 0 ( -.--% ) | - $ | 2024-03-30 |
Eti Mitrany active positions
| Companies | Position | Start |
|---|---|---|
| BRAINSWAY LTD. | Director/Board Member | 2016-06-04 |
| Trioxnano Ltd. | Director/Board Member | 2022-12-31 |
Former positions of Eti Mitrany
| Companies | Position | End |
|---|---|---|
CytoReason Ltd.
 CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | Director of Finance/CFO | 2022-11-30 |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 2019-12-31 |
| Copaxone | Director of Finance/CFO | - |
Training of Eti Mitrany
| Tel-Aviv University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| BRAINSWAY LTD. | Health Technology |
| Private companies | 3 |
|---|---|
| Trioxnano Ltd. | |
CytoReason Ltd.
CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | Technology Services |
| Copaxone |
- Stock Market
- Insiders
- Eti Mitrany